openPR Logo
Press release

Global Smart Inhalers Market Set for Rapid Growth, Driven by Increasing Respiratory Disorder Cases and Technological Advancements

10-29-2024 11:06 AM CET | Health & Medicine

Press release from: Emergen Research

Smart Inhalers Market

Smart Inhalers Market

The global smart inhalers market reached a value of USD 1.43 billion in 2022 and is projected to grow at an impressive compound annual growth rate (CAGR) of 18.9% over the forecast period. The growing number of respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD), along with rising demand for remote patient monitoring and personalized healthcare, are key factors driving this market growth.

Download Free Exclusive Sample PDF@ https://www.emergenresearch.com/request-for-customization/2565

Smart inhalers are advanced devices used to deliver medication directly to the lungs, providing relief for conditions such as asthma and COPD, which includes chronic bronchitis and emphysema. These devices help improve treatment adherence by sending dosage reminders, tracking usage, and ensuring patients take their medications correctly.

With respiratory disorders on the rise globally, the use of smart inhalers is increasing. Asthma affects 262 million people worldwide, while COPD impacts about 200 million individuals, causing 3.2 million deaths each year. Such widespread diseases highlight the urgent need for better respiratory treatments, where smart inhalers are playing a crucial role.

Key Market Drivers

The rising number of asthma and COPD cases is a major driver for the smart inhalers market. Lifestyle changes, higher pollution levels, and exposure to allergens are causing more people to develop these respiratory issues. Governments and health organizations are also raising awareness about the correct use of inhalers, further boosting demand for smart inhalers.

Additionally, smart inhalers can measure inhalation flow and monitor medication delivery, ensuring better coordination between the release of medication and the patient's breathing. This accuracy is important because incorrect use of traditional inhalers can result in up to 80% of the medication not reaching the lungs.

Technological innovations in the market are another growth factor. Companies are continuously developing and upgrading their smart inhaler devices. For example, in April 2023, Vivera Pharmaceuticals introduced ZICOH, an electronic, dose-controlled smart inhaler aimed at better managing and monitoring prescription drug use.

Challenges to Market Growth

Despite the positive outlook, the high cost of smart inhalers and limited awareness about respiratory disorders could hinder market growth, particularly in developing regions. The higher cost makes these devices less accessible for middle-income populations, which could slow adoption rates.

Product Insights

In terms of product types, the market is divided into Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs). MDIs accounted for the largest share of the market in 2022, thanks to their convenience and effectiveness in delivering respiratory medications. MDIs are compact and easy to use, providing patients with quick relief from symptoms. Their precise dosing also ensures that patients receive the correct amount of medication.

Meanwhile, DPIs are expected to see faster growth during the forecast period. DPIs offer a more user-friendly option, especially for patients who struggle with coordinating inhalation with dose release in MDIs. DPIs are also more environmentally friendly, as they do not require propellants.

Disease Segmentation

The market is also segmented by disease indication. The asthma segment is expected to hold the largest market share due to the growing number of asthma cases worldwide and increased research in this area. On the other hand, the COPD segment is projected to grow at the fastest rate, driven by the increasing number of COPD cases and exposure to environmental pollutants.

End-Use Insights

Hospitals and clinics are expected to remain the dominant end-users of smart inhalers. These institutions have specialized respiratory care units equipped with the latest technology and medical staff, making them the go-to places for treating asthma and COPD patients. The collaborative environment in hospitals and clinics also helps ensure that patients receive comprehensive care.

Interested in knowing more relevant information? Click here: https://www.emergenresearch.com/industry-report/smart-inhalers-market

Smart Inhalers Top Companies and Competitive Landscape

The global smart inhalers market is fairly fragmented, with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective smart inhalers solutions.

Some major players included in the global smart inhalers market report are:

H&T Presspart Manufacturing Ltd.
Personal Air Quality Systems Private Limited
COHERO Health Inc.
Cognita Labs
Adherium Limited
Amiko Digital Health Limited
Teva Pharmaceuticals Industries Ltd.
Propeller Health
Novartis AG
Pneuma Respiratory Inc.
3M Health Care Limited
AireHealth, Inc.
FindAir Sp. z o.o
Cohero health
GlaxoSmithKline
AstraZeneca
Propeller Health
Inspiro Medical
Boehringer Ingelheim
ResMed

Smart Inhalers Latest Industry Updates

On 23 July 2023, Teva Pharmaceutical Industries Ltd. launched its digitally-enabled inhaler named The GoResp Digihaler in the UK. It delivers inhaled corticosteroid budesonide and long-acting beta agonist formoterol and has built-in sensors that detect and record data on a patient's use and ability to use their inhaler. It connects to a smartphone via Bluetooth, allowing to view the results on a companion app and share the results with their healthcare provider.

On 7 July 2020, Novartis announced that the European Commission (EC) has
granted approval for Enerzair Breezhaler for use as a maintenance treatment for asthma in adult patients. These patients include who have not achieved adequate control with a maintenance combination of a Long‑Acting Beta2‑Agonist (LABA) and a high dose of an Inhaled Corticosteroid (ICS), and who have experienced one or more asthma exacerbations in the previous year. Enerzair Breezhaler, administered once daily, represents the first fixed-dose combination of LABA/Long-Acting Muscarinic Antagonist (LAMA)/ICS available in the EU for these specific patients.

Smart Inhalers Market Segmentation Analysis

For the purpose of this report, Emergen Research has segmented the global smart inhalers market on the basis of product, disease indication, distribution channel, end-use, and region:

Product Outlook (Revenue, USD Billion; 2019-2032)

Dry Powder Inhaler
Metered Dose Inhaler

Disease indication Outlook (Revenue, USD Billion; 2019-2032)

Chronic Obstructive Pulmonary Disease (COPD)
Asthma
Others

Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

End-use Outlook (Revenue, USD Billion; 2019-2032)

Hospitals and Clinics
Respiratory Care Centers
Others

Make Payment [Buy your Exclusive copy] @ https://www.emergenresearch.com/select-license/2565

Regional Outlook (Revenue, USD Billion; 2019-2032)

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of Middle East & Africa

Contact Us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Smart Inhalers Market Set for Rapid Growth, Driven by Increasing Respiratory Disorder Cases and Technological Advancements here

News-ID: 3713720 • Views:

More Releases from Emergen Research

Global Internet of Things (IoT) in Healthcare Market to Reach USD 299.05 Billion in 2023, Set for Strong Growth at 16.5% CAGR
Global Internet of Things (IoT) in Healthcare Market to Reach USD 299.05 Billion …
The global Internet of Things (IoT) in Healthcare Market was valued at USD 299.05 billion in 2023 and is expected to grow at a CAGR of 16.5% during the forecast period. This growth is fueled by the rising use of connected healthcare devices, increasing demand for early disease detection through remote monitoring, and growing adoption of artificial intelligence (AI) tools within IoT-based healthcare systems. The market is also benefiting from the
Global Stem Cell Therapy Market to Reach USD 49.2 Billion by 2034, Growing at 13.6% CAGR
Global Stem Cell Therapy Market to Reach USD 49.2 Billion by 2034, Growing at 13 …
The global Stem Cell Therapy Market, valued at USD 13.7 billion in 2024, is projected to reach USD 49.2 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.6%. Growth is being fueled by the rising burden of chronic diseases, rapid progress in cell-based studies, and increasing investments in regenerative medicine and personalized healthcare solutions. Stem cell therapies offer the ability to repair, replace, or restore damaged tissues
Artificial Intelligence Strengthens Cybersecurity as Threats Grow More Sophisticated
Artificial Intelligence Strengthens Cybersecurity as Threats Grow More Sophistic …
The global Artificial Intelligence in cybersecurity market size was USD 23.8 Billion in 2023 and is expected to reach a market valuation of USD 29.44 billion by the end of 2024 registering a CAGR of 23.7% during the forecast period. The adoption of Artificial Intelligence (AI) in cybersecurity is rapidly gaining traction as organizations worldwide face increasingly complex and frequent cyber threats. By combining advanced technologies such as Machine Learning
Global Regenerative Medicine Market to Reach USD 125.6 Billion by 2034, Growing at 13.9% CAGR
Global Regenerative Medicine Market to Reach USD 125.6 Billion by 2034, Growing …
The global regenerative medicine market, valued at USD 34.2 billion in 2024, is set to grow to USD 125.6 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.9%. Growth is being fueled by rising approvals of advanced therapies, strong demand for personalized treatments in cancer and orthopedics, and expanding cell and gene therapy manufacturing across major markets such as North America, Europe, and Asia. Once seen as

All 5 Releases


More Releases for Inhaler

12-09-2024 | Health & Medicine
Getnews
Z!NGHA Introduces Dual-Chamber Aromatherapy Nasal Inhaler
Image: https://www.getnews.info/uploads/e696f4bdf98524eaf4f4f4bc89f2369f.jpg Miami, FL - December 09, 2024 - Z!NGHA, a new player in the wellness space, is thrilled to announce the launch of its flagship product, the Z!NGHA Double Nasal Inhaler, an innovation that combines the therapeutic benefits of aromatherapy and essential oils with the on-the-go convenience of a dual-chamber nasal inhaler. Unlike the industry standard single chamber nasal inahlers, Z!ngha offers simultaneous inhalation through both nostrils, redefining aromatherapy for
Asthma Inhaler Device Market By Type (Metered-dose inhaler, MDI with a spacer, D …
The Asthma Inhaler Device Market is expected to grow at a CAGR of 6.42% during the forecast period. The market is also expected to reach a revenue of USD 19677.54 million by the end of 2022-2030. The research report on the market for asthma inhaler devices offers analysis and insights into the numerous aspects that are anticipated to be present over the course of the forecast period as well as
Increasing Number Of Launches In Generic Version Of Budesonide Inhaler Drive The …
Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. According to World Health Organization (WHO), asthma
Oxygen Inhaler Market Size, Share, Growth & Forecast 2026
Global Oxygen Inhaler Market report focuses on Oxygen Inhaler volume and value at global level, regional level and company level. From a global perspective, this report represents the overall Oxygen Inhaler market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for
Global Digital Dose Inhaler Market Insights, Forecast
Digital Dose Inhaler is a kind of medical instrument. Digital Dose Inhaler enable patients to the number of tracking has consumed doses. The global Digital Dose Inhaler market is valued at 1790 million US$ in 2018 and will reach 3540 million US$ by the end of 2025, growing at a CAGR of 8.9% during 2019-2025. The objectives of this study are to define, segment, and project the size of the
Dry Powder Inhaler Market Report 2018: Segmentation by Product (Single Dose Dry …
Global Dry Powder Inhaler market research report provides company profile for Astrazeneca Plc., 3M Company, GlaxoSmithKline Plc, Novartis AG, Cipla Ltd., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., MannKind Corporation and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and